The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.
Cancer patients frequently develop neuropathy as a results of chemotherapy agents including oxaliplatin, paclitaxel, vinca alkaloids, and Velcade. Because many such patients have extended survival or receive treatment with curative intent, the resultant neuropathy can limit quality of life significantly....
Carfilzomib is a nvelo prteosome inhibitor. Bortezomib, the only proteosome inhibitor that is currently FDA approve, has shown significant activity in myeloma and mantle cell NHL and is being tested in other hematologic malignancies. If Carfilzomib has improved toxicty and greater efficacy...
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...